Watch BDTX. Know when insiders buy.
One email the day a filing lands. Free.
BDTX
Black Diamond Therapeutics, Inc.
2.10
−0.02 −0.94%
USD · close Sep 8
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
37
FLAG · shorts 37
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $120.7MP/E —DIV YIELD —FCF YIELD —REV TTM —NET INCOME −$42.6M −394.7%NET CASH —52W 1.61 – 4.87SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$12.1M | −$9.9M | — | -0.17 | −$8M | — | — | Aug 5 |
| Q1 2026 · Mar 31 | — | — | — | −$11.3M | −$9M | −116.0% | -0.16 | −$10.2M | — | — | Aug 5 |
| Q4 2025 · Dec 31derived | — | — | — | −$17.6M | −$15.1M | — | -0.26 | −$6.8M | — | — | Mar 16 |
| Q3 2025 · Sep 30 | — | — | — | −$11M | −$8.5M | — | -0.15 | −$7.8M | — | — | Nov 6 |
| Q2 2025 · Jun 30 | — | — | — | −$13.4M | −$10.6M | — | -0.19 | −$9.2M | — | — | Aug 5 |
| Q1 2025 · Mar 31 | — | — | — | $54.5M | $56.5M | — | 0.98 | $53.4M | — | — | Aug 5 |
| Q4 2024 · Dec 31derived | — | — | — | −$18.3M | −$16M | — | -0.28 | −$15.1M | $0 | −$15.1M | Mar 16 |
| Q3 2024 · Sep 30 | — | — | — | −$18.1M | −$15.6M | — | -0.28 | −$11.3M | — | — | Nov 6 |
| Q2 2024 · Jun 30 | — | — | — | −$22.1M | −$19.9M | — | -0.36 | −$14.7M | — | — | Nov 6 |
| Q1 2024 · Mar 31 | — | — | — | −$20.2M | −$18.2M | — | -0.35 | −$21.2M | — | — | Nov 6 |
| Q4 2023 · Dec 31derived | — | — | — | −$20.9M | −$19.4M | — | -0.34 | −$14M | $0 | −$14M | Mar 6 |
| Q3 2023 · Sep 30 | — | — | — | −$24M | −$23M | — | -0.45 | −$18.4M | $33K | −$18.4M | Nov 5 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | $12.5M | $22.4M | — | 0.39 | $29.6M | — | — | — | — |
| FY2024 · to Dec 31 | — | — | −$78.8M | −$69.7M | — | -1.27 | −$62.3M | $0 | −$62.3M | — | — |
| FY2023 · to Dec 31 | — | — | −$86.5M | −$82.4M | — | -1.88 | −$66.7M | $33K | −$66.8M | — | — |
| FY2022 · to Dec 31 | — | — | −$92.8M | −$91.2M | — | -2.52 | −$85.1M | $192K | −$85.3M | — | — |
| FY2021 · to Dec 31 | — | — | −$126.9M | −$125.6M | — | -3.47 | −$100.1M | $2.7M | −$102.9M | — | — |
| FY2020 · to Dec 31 | $0 | — | −$69.6M | −$67.3M | — | -2.05 | −$52.1M | $142K | −$52.3M | — | — |
Every number comes from Black Diamond Therapeutics, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.